EU/3/16/1783

Table of contents

About

On 18 November 2016, orphan designation (EU/3/16/1783) was granted by the European Commission to EMAS Pharma Limited, United Kingdom, for N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide (also called CM4620) for the treatment of acute pancreatitis.

The sponsorship was transferred to Cogas Pharma Limited, Ireland in April 2017.

The sponsorship was transferred to Reglntel Ltd, Ireland in July 2018.

Key facts

Active substance
N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide
Disease / condition
Treatment of acute pancreatitis
Date of first decision
18/11/2016
Outcome
Positive
EU designation number
EU/3/16/1783

Sponsor's contact details

Reglntel Ltd
Templetown
Carlingford
County Louth
Ireland
Tel. +353 (0)42 9376 740
E-mail: bmartin@regintel.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating